Pegfilgrastim in Patients With Alcoholic Hepatitis
Status:
Completed
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
This is a multi-center, prospective, randomized trial of standard of care vs. standard of
care + pegfilgrastim (Neulasta®) among patients with a clinical diagnosis of alcoholic
hepatitis and DF≥32.
Phase:
Phase 2
Details
Lead Sponsor:
Timothy Morgan, MD
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)